Group 2:PD-1 inhibitor+lenvatinib

2 trials

Sponsors

Affiliated Tumor Hospital of Guangxi Medical University, Cancer Hospital Affiliated to Guangxi Medical University

Conditions

Primary liver cancer

Early Phase 1

Clinical study on the efficacy and safety of HAIC/PD-1 inhibitor combined with lenvatinib in the treatment of unresectable primary liver cancer

RecruitingChiCTR2000035078

Affiliated Tumor Hospital of Guangxi Medical UniversityPrimary liver cancer

Start: 2020-08-01Updated: 2020-08-03

Clinical study of HAIC compared with targeted and immunotherapy in patients with high-risk recurrence of HCC

RecruitingChiCTR2000035081

Cancer Hospital Affiliated to Guangxi Medical UniversityPrimary liver cancer

Start: 2020-08-01Updated: 2020-08-03